OptiBiotix Health (LSE:OPTI) reported strong financial progress for 2025, with revenue increasing 34% to £1.17 million and gross profit climbing 85% to £614,000. Gross margins also improved significantly to 53%, supported by continued expansion in international markets, particularly across Asia, which now contributes 73% of total group revenue.
The company ended the year with cash reserves of £1.04 million and no debt, while its listed shareholdings in ProBiotix Health and SkinBioTherapeutics were valued at approximately £6.45 million. OptiBiotix also carried forward an additional £212,000 of customer orders into the 2026 financial year.
International Expansion and Product Development Drive Momentum
Operationally, the business continued expanding the commercial reach of its SlimBiome weight-management ingredient, including its launch within the Hydroxycut brand in the United States. The company also secured a new distribution agreement with a major direct-selling weight management company and reported rapid growth across Asian markets, where 17 products have now launched.
OptiBiotix additionally introduced an upgraded enzyme-based production process for SweetBiotix, designed to improve manufacturing yields, reduce costs and enhance taste performance. Alongside this, its WellBiome platform is being evaluated in a hospital-led clinical study examining potential reductions in intensive care stays and healthcare costs.
Record Order Intake Supports 2026 Outlook
The company entered 2026 with strong commercial momentum, reporting record order intake early in the year. This included a 24-tonne SlimBiome order in Taiwan and total January orders exceeding £800,000.
Management said its strategic priorities are now evolving from rapid expansion toward achieving commercial sustainability and improved profitability. Planned measures include annual cost reductions of between £500,000 and £600,000, lower SlimBiome production expenses and the introduction of dedicated business-unit profit and loss accountability by the end of 2026.
Financial Challenges Still Influence Outlook
The company’s outlook is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.
More about OptiBiotix Health
OptiBiotix Health is a UK-listed life sciences company focused on microbiome-based ingredients and products designed to reduce hunger and food cravings, improve gut health and offer sweet fibre sugar substitutes. Its core portfolio includes prebiotic brands such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, complemented by interests in skincare and probiotics via stakes in SkinBioTherapeutics and ProBiotix Health.
Leave a Reply